Cancer Vaccines as Immunotherapy of Cancer
- 1st Edition - March 4, 2022
- Imprint: Academic Press
- Editors: Luigi Buonaguro, Sjoerd Van Der Burg
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 9 0 1 - 8
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 9 0 2 - 5
Cancer Vaccines as Immunotherapy of Cancer provides extensive and state-of-the-art information about the meaning, relevance and limitation of therapeutic cancer vaccines. It covers… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCancer Vaccines as Immunotherapy of Cancer provides extensive and state-of-the-art information about the meaning, relevance and limitation of therapeutic cancer vaccines. It covers all the aspects involved in the vaccine research and development (identification of optimal target antigens, formulations, delivery strategies, adjuvants among others) as well as their use in combination with other immunomodulatory approaches.
The book discusses topics such as identification of tumor associated and specific antigens, proteogenomic for identification of novel target tumor antigens, antigen-specific T cells, and Peptide and RNA based vaccines. Additionally, it covers oncolytic viruses for antigen delivery, cancer vaccine targeting viral antigens and combinatorial immunotherapy strategies.
Written by leading experts worldwide, this is a valuable resource for cancer researchers, oncologists and members of biomedical field who wants to understand in depth the recent findings in the field of cancer vaccines.
- Describes the state-of-the-art of the research and development of therapeutic cancer vaccines
- Presents detailed diagrams to help the reader understand the functionality of each type of vaccine discussed
- Encompasses recent findings in the field through chapters written by leading experts worldwide
Cancer researchers, oncologists, medical scientists, clinicians, graduate students, pharmaceutical scientists
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- About the editors
- Preface
- Chapter 1. Oncolytic viruses for antigen delivery
- Abstract
- Introduction
- Antitumor immunity induced by OVs
- Targeting tumor antigens for cancer treatment
- OVs confer neoantigen immunity
- OVs in combination therapies
- OV-based anticancer vaccines
- OVs as platforms for personalized anticancer vaccines
- Conclusions
- References
- Chapter 2. Tumor lysates cancer vaccine
- Abstract
- Introduction
- Personalized cancer treatment with whole-tumor lysate vaccine
- Preparation of whole-tumor cell lysate vaccine
- Methods of administrating whole-tumor cell lysate vaccine
- Combinatorial therapeutic approaches to increase whole-tumor cell lysate vaccine efficacy
- Conclusion
- References
- Chapter 3. Tumor antigens for preventative cancer vaccines
- Abstract
- Introduction
- Cancer immunoprevention
- Targeted tumor antigens
- Primary prevention
- Secondary prevention: preventing progression to invasive cancer
- Tertiary immunoprevention: avoiding recurrence
- Concluding remarks
- References
- Chapter 4. Regulatory aspects of cancer immunotherapy in Europe
- Abstract
- Introduction
- Definition of vaccines within the EU legislation
- Classification
- Consequences of medicinal product classification
- Traceability
- Marketing authorization
- Production
- Quality requirements
- Preclinical and clinical studies
- Pharmacovigilance
- Batch release
- Conclusion
- References
- Chapter 5. Identification of tumor antigens for T-cell-mediated cancer immunotherapy
- Abstract
- Introduction
- Antigen processing and presentation
- The human leukocyte antigen system
- Isolation of human leukocyte antigen ligands from tumor tissues or other sources
- Identification of human leukocyte antigen ligands by mass spectrometry
- The impact of information derived from DNA and RNA sequencing
- The impact of human leukocyte antigen ligand prediction tools
- How to find cancer-specific ligands?
- Use of information on tumor antigens for therapy
- Conclusion
- Acknowledgments
- References
- Chapter 6. Therapeutic cancer vaccines targeting viral antigens
- Abstract
- Introduction
- Immunotherapy, including therapeutic vaccination against cancers caused by Epstein–Barr virus
- Therapeutic vaccination against cancers caused by human T-cell lymphotropic virus type 1
- Therapeutic vaccination against hepatitis B virus
- Therapeutic vaccination against hepatitis C virus
- Therapeutic vaccination against high-risk human papilloma virus
- Therapeutic vaccination against Merkel carcinoma virus
- References
- Chapter 7. Novel dendritic cell vaccine strategies
- Abstract
- Introduction
- Conclusions
- Acknowledgments
- References
- Chapter 8. Combinatorial immunotherapy strategies for cancer vaccines
- Abstract
- Introduction
- Immune modulatory approaches to increase tumor immunogenicity and potentiate cancer vaccines
- Conclusions and perspectives
- References
- Chapter 9. Peptide-based vaccines
- Abstract
- Introduction
- Vaccine targets
- Peptide vaccines targeting tumor-associated antigens
- Peptide-based vaccines targeting onco-viral proteins
- Peptide-based vaccines targeting neoepitopes
- Short versus long synthetic peptides
- Formulation of peptide-based vaccines
- Peptide-based vaccines in combination with additional immune modulators
- Vaccines in combination with cytokines and immunocytokines
- Vaccines in combination with radiation and chemotherapy
- Vaccines in combination with checkpoint blockade
- Reversion of mesenchymal-like features
- Multicombination therapies
- Concluding remarks
- Abbreviations
- Acknowledgment
- References
- Chapter 10. Personalized peptide vaccines
- Abstract
- Introduction
- Limitation of TAA-derived peptides for cancer vaccines
- Potential of neoantigen peptides
- Procedure of personalized peptide vaccines targeting neoantigens
- Clinical trials of personalized vaccines targeting neoantigens
- Challenges to overcome the current limitations
- Conclusion
- References
- Chapter 11. Antigen-specific T cells
- Abstract
- Tools to detect antigen-specific T cells and identify vaccine targets
- References
- Chapter 12. Adjuvants for improving cancer vaccines
- Abstract
- Introduction
- Adjuvants
- Signal 1: adjuvants targeting innate immunity
- Signal 2: adjuvants harnessing costimulatory mechanisms
- Signal 3: overcoming tumor regulatory mechanisms
- Combinatorial adjuvants
- Conclusions and future prospects
- Acknowledgment
- References
- Chapter 13. Nucleic acid-based vaccines
- Abstract
- Overview
- DNA-based vaccines
- RNA-based vaccines
- Genetic vaccines in human clinical trials
- Conclusions
- References
- Index
- Edition: 1
- Published: March 4, 2022
- No. of pages (Paperback): 272
- No. of pages (eBook): 272
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780128239018
- eBook ISBN: 9780128239025
LB
Luigi Buonaguro
Luigi Buonaguro, PhD, is Head of Cancer Immunoregulation Unity at National Cancer Institute “Pascale” in Italy. His primary interest is the identification of novel target tumor antigens. In particular, Dr. Buonaguro is coordinating the development of a novel therapeutic cancer vaccine for liver cancer.
Affiliations and expertise
Head of Cancer Immunoregulation Unity, National Cancer Institute “Pascale”, ItalySV
Sjoerd Van Der Burg
Sjoerd Van Der Burg, PhD, is Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, at Leiden University Medical Center, in The Netherlands. His primary interest is the exploration of key factors in host-tumor interactions that determine successes and failures in the immunotherapy of cancer. Dr. Van Der Burg co-developed the synthetic long peptide vaccine concept, in particular for HPV-induced cancers and currently is developing a vaccine to stimulate the immune response to TAP-deficient tumors.Sjoerd Van Der Burg, PhD, is Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, at Leiden University Medical Center, in The Netherlands. His primary interest is the exploration of key factors in host-tumor interactions that determine successes and failures in the immunotherapy of cancer. Dr. Van Der Burg co-developed the synthetic long peptide vaccine concept, in particular for HPV-induced cancers and currently is developing a vaccine to stimulate the immune response to TAP-deficient tumors.
Affiliations and expertise
Head of Experimental Cancer Immunology and Therapy Institute and of Research Laboratories Medical Oncology, Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, The NetherlandsRead Cancer Vaccines as Immunotherapy of Cancer on ScienceDirect